LLY · News · 20261112N
Competition and market share - oral GLP-1
ELI LILLY & Co · 2026-11-12 · Importance 41 · Surprise 60 · In source text
China approved Eli Lilly’s oral GLP-1 weight-loss drug orforglipron, making Lilly the first company cleared to sell a GLP-1 weight-loss pill in the country. The approval gives Lilly an early lead over Novo Nordisk in China’s emerging oral obesity-treatment market. Orforglipron will compete with injectable GLP-1 treatments from Novo Nordisk, Pfizer and China’s Innovent Biologics; Novo’s oral Wegovy had not yet been approved in China. China’s National Health Commission has estimated that more than 65% of the population could be overweight or obese by 2030, and both Lilly and Novo see pills as a way to reach patients reluctant to use injections.
Key facts
- Foundayo launched in April 2026 as an oral GLP-1 obesity treatment. source
- Foundayo recorded $281 million in sales in 2026 so far. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Foundayo launched in April 2026 as an oral GLP-1 obesity treatment. |